Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 40
- 主要终点
- Changes of portal vein thrombosis
研究概览
简要总结
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 18-75
- •diagnosed as portal hypertension by contrast-enhanced computed tomography
- •diagnosed as JAK2 positive
排除标准
- •not had portal contrast-enhanced computed tomography
- •not had JAK2 mutation test
- •other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors
研究组 & 干预措施
Anticoagulation group
Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.
干预措施: Anticoagulation Agents (Drug)
结局指标
主要结局
Changes of portal vein thrombosis
时间窗: 1 year
The changes of portal vein thrombosis including progression, disappear or unchanged.
次要结局
- Overall survival(1 year)
- The occurrence of variceal bleeding(1 year)
研究者
XiaoquanHUANG
Resident
Shanghai Zhongshan Hospital